SCHEMBL2394883

SCHEMBL2394883

COC(=O)c1cscc1NC=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
ATM Q13315 1/20 0.37
PTPN1 P18031 1/20 0.36
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
ALDH1A1 P00352 3/20 0.34
CFTR P13569 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
KMT2A Q03164 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
CYP2A6 P11509 1/20 0.34
FABP6 P51161 1/20 0.34
OR51E2 Q9H255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68934 0.78 TSHR (0.46) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL14197656 0.78 MAPK8 (0.45) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL13088443 0.77 ALDH1A1 (0.41) KDM4EPOLBATMTSHRLMNA
SCHEMBL6220756 0.76 MAPT (0.51) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL4066272 0.75 MAPK8 (0.52) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL3723136 0.74 ALDH1A1 (0.40) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL11223756 0.73 MAPK10 (0.54) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL2442267 0.73 KDM4E (0.65) KDM4EPOLBATMTSHRLMNA
SCHEMBL29483352 0.73 KDM4E (0.65) KDM4EPOLBATMTSHRLMNA
SCHEMBL15635870 0.72 MAPK8 (0.44) MAPK8MAPK9MAPK10KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2719701-B1 Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides GILEAD SCIENCES INC (US) 2017-04-05 EP disclosed
EP-2719701-B1 Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides GILEAD SCIENCES INC (US) 2017-04-05 EP disclosed
EP-2719701-A1 methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides GILEAD SCIENCES, INC. (US) 2014-04-16 EP disclosed
EP-2719701-A1 methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides GILEAD SCIENCES, INC. (US) 2014-04-16 EP disclosed
EP-2396340-B1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2013-12-18 EP disclosed
US-8012942-B2 Carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-09-06 US disclosed
US-8012942-B2 Carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-09-06 US disclosed
US-8012942-B2 Carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2011-09-06 US disclosed
WO-2010093608-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-19 WO disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
US-6541630-B1 7-bromo-3-methyl-3,4- dihydrothieno(3,2-d)pyrimidin-4-one AGREVO UK LIMITED (GB) 2003-04-01 US disclosed
EP-0982992-B1 Use of thienopyrimidines as fungicides AVENTIS CROPSCIENCE UK LTD (GB) 2002-09-25 EP disclosed
US-6432964-B1 A THIENYLPYRIMIDINE COMPOUND AGREVO UK LIMITED (GB) 2002-08-13 US disclosed
EP-0982992-A1 FUNGICIDES AgrEvo UK Limited (GB) 2000-03-08 EP disclosed
WO-1998049899-A1 FUNGICIDES AGREVO UK LIMITED (GB) 1998-11-12 WO disclosed
EP-0452002-A2 Thienopyrimidine derivatives DOWELANCO (US) 1991-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, TYMP, MTAP MAPK8 2656/4885MAPK9 3396/4885MAPK10 3583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.